Sab biotherapeutics awarded $35.6m from u.s. department of defense for covid-19 and scaling rapid response antibody program

Sab biotherapeutics awarded $35.6m from u.s. department of defense for covid-19 therapeutic and scaling rapid response antibody program.

KTOS Ratings Summary

KTOS Quant Ranking